RxDoctor Payments Data

John Ivanoff, MD

Interventional Cardiology · Tulsa, OKNPI 1497725857

Payments from drug & device makers

$5,680in general payments, 2019–2025

Across 266 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$882
  • Pfizer$723
  • Abbott$596
  • AstraZeneca$431
  • Amgen$429
  • Merck$346
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,680100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,680 in reported general payments places this provider in the 40th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$194,077
Medicare patients
2,838
Services billed
5,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban539$428,788
XareltoRivaroxaban124$129,699
EntrestoSacubitril/Valsartan121$125,719
JardianceEmpagliflozin88$91,869
FarxigaDapagliflozin Propanediol107$79,763
Repatha SureclickEvolocumab54$48,115
MultaqDronedarone Hcl42$39,522
Praluent PenAlirocumab11$14,077
Metoprolol Succinate454$8,537
Atorvastatin Calcium413$7,261
NexletolBempedoic Acid16$6,167
Valsartan153$4,364
Rosuvastatin Calcium131$4,296
ClopidogrelClopidogrel Bisulfate268$3,732
Carvedilol359$3,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$723$428,788539 claims
Johnson & JohnsonXarelto$299$129,699124 claims
NovartisEntresto$882$125,719121 claims
Boehringer IngelheimJardiance$312$91,86988 claims
AstraZenecaFarxiga$431$79,763107 claims
Sanofi-aventis U.S. LLCMultaq$201$39,52242 claims
Esperion Therapeutics, Inc.Nexletol$250$6,16716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →